Related Experiment Videos
rpoB mutation conferring rifampin resistance in Streptococcus pyogenes
Hélène Aubry-Damon1, Marc Galimand, Guy Gerbaud
1Unité des Agents Antibactériens, Institut Pasteur, 75724 Paris Cedex 15, France.
Antimicrobial Agents and Chemotherapy
|April 18, 2002
Summary
High-level rifampin resistance in Streptococcus pyogenes and Staphylococcus aureus was linked to specific mutations in the rpoB gene. These genetic changes explain how bacteria can evade rifampin treatment.
Area of Science:
- Microbiology
- Molecular Biology
- Genetics
Background:
- Streptococcus pyogenes and Staphylococcus aureus are significant human pathogens.
- Rifampin is a crucial antibiotic for treating various bacterial infections.
- Antibiotic resistance, particularly to rifampin, poses a growing global health threat.
Purpose of the Study:
- To investigate the genetic basis of high-level rifampin resistance in clinical isolates of S. pyogenes and S. aureus.
- To identify specific mutations in the rpoB gene associated with rifampin resistance.
Main Methods:
- Bacterial isolates (S. pyogenes BM4478, S. aureus BM4479) were obtained from a patient undergoing rifampin therapy.
- The rpoB gene, encoding the beta-subunit of RNA polymerase, was analyzed for mutations.
Main Results:
- Streptococcus pyogenes BM4478 exhibited a Ser522Leu mutation in the rpoB gene.
- Staphylococcus aureus BM4479 displayed two mutations: His526Asn and Ser574Leu in the rpoB gene.
- These identified mutations correlate with the observed high-level rifampin resistance.
Conclusions:
- Specific mutations in the rpoB gene are responsible for high-level rifampin resistance in these clinical isolates.
- Understanding these resistance mechanisms is vital for effective antibiotic therapy and combating antimicrobial resistance.